Arcus Biosciences (NYSE:RCUS) President Sells $437,135.72 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 15,764 shares of Arcus Biosciences stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $27.73, for a total transaction of $437,135.72. Following the completion of the sale, the president owned 897,240 shares of the company’s stock, valued at $24,880,465.20. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Arcus Biosciences Trading Up 2.3%

RCUS opened at $30.93 on Friday. Arcus Biosciences, Inc. has a 52 week low of $7.91 and a 52 week high of $31.44. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The business has a fifty day simple moving average of $24.82 and a 200-day simple moving average of $23.01. The firm has a market cap of $3.89 billion, a P/E ratio of -9.73 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm had revenue of $17.00 million during the quarter, compared to analysts’ expectations of $29.48 million. During the same quarter in the prior year, the firm posted ($1.14) EPS. Arcus Biosciences’s quarterly revenue was down 39.3% compared to the same quarter last year. On average, equities analysts expect that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Several large investors have recently bought and sold shares of RCUS. GAMMA Investing LLC boosted its stake in shares of Arcus Biosciences by 17.5% in the 4th quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after buying an additional 482 shares during the period. Royal Bank of Canada increased its stake in shares of Arcus Biosciences by 14.6% during the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock worth $102,000 after buying an additional 607 shares during the period. Creative Planning raised its holdings in Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after acquiring an additional 771 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after acquiring an additional 881 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its stake in Arcus Biosciences by 1.1% in the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock worth $2,203,000 after acquiring an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on RCUS shares. Citigroup increased their price target on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Leerink Partners set a $47.00 price objective on shares of Arcus Biosciences in a report on Monday, April 20th. Morgan Stanley upped their target price on shares of Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Monday, May 11th. Truist Financial started coverage on shares of Arcus Biosciences in a report on Monday, May 18th. They set a “buy” rating and a $35.00 target price on the stock. Finally, The Goldman Sachs Group raised their price target on shares of Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.10.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.